Lux Biosciences Raises $50 Million
Lux Biosciences Inc., a Jersey City, N.J.-based biotech company focused on ophthalmic diseases, has raised $50 million in Series B funding. Return backers includeHBM Bioventures, Novo A/S, Prospect Venture Partners and SV Life Sciences and SVLS' publicly traded fund International Biotechnology Trust plc. Lux Biosciences had raised a $49 million Series A round in 2006.
19 October 2009•4 mins read
